Towards Personalized Treatment of Prostate Cancer: PSMA I&T, a Promising Prostate-Specific Membrane Antigen-Targeted Theranostic Agent
Theranostics
2016
6
6
849-861
68Ga-Pentixafor-PET/CT for Imaging of Chemokine Receptor 4 Expression in Glioblastoma
Theranostics
2016
6
3
428-434
Targeted positron emission tomography imaging of CXCR4 expression in patients with acute myeloid leukemia
Haematologica
2016
101
8
932-940
Imaging the Cytokine Receptor CXCR4 in Atherosclerotic Plaques with the Radiotracer
68
Ga-Pentixafor for PET
Journal of Nuclear Medicine
2016
58
3
499-506
Preclinical Evaluation and First Patient Application of
99m
Tc-PSMA-I&S for SPECT Imaging and Radioguided Surgery in Prostate Cancer
Journal of Nuclear Medicine
2016
58
2
235-242
Radiation Dosimetry for
177
Lu-PSMA I&T in Metastatic Castration-Resistant Prostate Cancer: Absorbed Dose in Normal Organs and Tumor Lesions
Journal of Nuclear Medicine
2016
58
3
445-450
Tumor Uptake of Anti-CD20 Fabs Depends on Tumor Perfusion
Journal of Nuclear Medicine
2016
57
12
1971-1977
Variation of Specific Activities of 68Ga-Aquibeprin and 68Ga-Avebetrin Enables Selective PET Imaging of Different Expression Levels of Integrins 5 1 and v 3
Journal of Nuclear Medicine
2016
57
10
1618-1624
PSMA-Based Radioligand Therapy for Metastatic Castration-Resistant Prostate Cancer: The Bad Berka Experience Since 2013
Journal of Nuclear Medicine
2016
57
Supplement_3
97S-104S
177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy
Journal of Nuclear Medicine
2016
57
7
1006-1013